Format

Send to

Choose Destination
Nat Rev Drug Discov. 2013 Feb;12(2):147-68. doi: 10.1038/nrd3930. Epub 2013 Jan 21.

Clinical targeting of the TNF and TNFR superfamilies.

Author information

1
Division of Immune Regulation, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA. mick@liai.org

Abstract

Inhibitors of tumour necrosis factor (TNF) are among the most successful protein-based drugs (biologics) and have proven to be clinically efficacious at reducing inflammation associated with several autoimmune diseases. As a result, attention is focusing on the therapeutic potential of additional members of the TNF superfamily of structurally related cytokines. Many of these TNF-related cytokines or their cognate receptors are now in preclinical or clinical development as possible targets for modulating inflammatory diseases and cancer as well as other indications. This Review focuses on the biologics that are currently in clinical trials for immune-related diseases and other syndromes, discusses the successes and failures to date as well as the expanding therapeutic potential of modulating the activity of this superfamily of molecules.

PMID:
23334208
PMCID:
PMC3625401
DOI:
10.1038/nrd3930
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center